All Companies
ABBVCongressional Stock Trades
ABBVIE INC.
Pharmaceutical Preparations
Congressional stock trades in ABBVIE INC. (ABBV) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
37
Politicians Trading
13
Last Traded
Jun 2, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Julia LetlowR | Jan 13, 2026 | Dec 8, 2025 | Sell | $1,001 - $15,000 | +18.30% |
| Julia LetlowR | Jan 13, 2026 | Apr 28, 2025 | Buy | $1,001 - $15,000 | +37.24% |
| Julia LetlowR | Jan 13, 2026 | Jan 24, 2025 | Sell | $1,001 - $15,000 | +55.00% |
| Lisa C. McClainR | Nov 21, 2025 | Oct 31, 2025 | Sell | $1,001 - $15,000 | +21.06% |
| Lisa C. McClainR | Nov 21, 2025 | Oct 30, 2025 | Buy | $1,001 - $15,000 | +15.67% |
| Lisa C. McClainR | Nov 21, 2025 | Oct 30, 2025 | Sell | $1,001 - $15,000 | +15.67% |
| Marjorie Taylor GreeneR | Aug 15, 2025 | Aug 4, 2025 | Buy | $1,001 - $15,000 | +33.86% |
| Lisa C. McClainR | Aug 13, 2025 | Jul 22, 2025 | Sell | $1,001 - $15,000 | +41.07% |
| Lisa C. McClainR | Aug 13, 2025 | Jul 22, 2025 | Buy | $1,001 - $15,000 | +41.07% |
| Lisa C. McClainR | Aug 13, 2025 | Jun 17, 2025 | Buy | $1,001 - $15,000 | +42.31% |
| Robert BresnahanR | Jun 9, 2025 | May 15, 2025 | Buy | $1,001 - $15,000 | +45.29% |
| Jefferson ShreveR | May 8, 2025 | Apr 17, 2025 | Sell | $50,001 - $100,000 | +52.59% |
| Robert BresnahanR | May 8, 2025 | Apr 8, 2025 | Sell | $1,001 - $15,000 | +50.26% |
| Marjorie Taylor GreeneR | May 6, 2025 | May 5, 2025 | Buy | $1,001 - $15,000 | +34.63% |
| Robert BresnahanR | Mar 27, 2025 | Feb 25, 2025 | Buy | $1,001 - $15,000 | +29.30% |
| Marjorie Taylor GreeneR | Mar 19, 2025 | Mar 17, 2025 | Buy | $1,001 - $15,000 | +23.08% |
| Jefferson ShreveR | Mar 9, 2025 | Feb 24, 2025 | Buy | $50,001 - $100,000 | +29.34% |
Price History
About ABBVIE INC.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.